Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Status:
Recruiting
Trial end date:
2023-10-12
Target enrollment:
Participant gender:
Summary
This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with
spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in
adult subjects with advanced solid tumors.
These two treatment arms will enroll subjects in parallel to characterize the safety,
tolerability, PK, PD and preliminary antitumor activity.
The study treatment will be administered until the subject experiences unacceptable toxicity,
progressive disease, and/or has treatment discontinued at the discretion of the Investigator
or the subject, or due to withdrawal of consent.